Chapter 2 40 20. Albin N, Chassagnol F, Bergmann JF. Early access to health products in France: Major advances of the French “Conseil stratégique des industries de santé” (CSIS) to be implemented (modalities, regulations, funding). Therapie. 2019;74(1):103117. doi:10.1016/j.therap.2018.12.002 21. Polak TB, Cucchi DGJ, van Rosmalen J. [Expanded Access in The Netherlands: prescribing unregistered medicine]. Ned Tijdschr Geneeskd. 2021;165:1-5. 22. BASG. Information on Named Patient Use (Heilversuch) in Austria - Definition and Framework.; 2015. http://www.basg.gv.at/en/ pharmacovigilance/ 23. Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of Compassionate Use Programs in the European Union member states. Intractable Rare Dis Res. 2016;5(4):244-254. doi:10.5582/ irdr.2016.01054 24. Bunnik EM, Aarts N, van de Vathorst S. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs. Health Policy Amst Neth. 2018;122(9):977-983. doi:10.1016/j. healthpol.2018.06.005 25. Fernandez Lynch H, Salam T, Gould P, Bateman-House A, Kimberly L. Navigating the Expanded Access Pathway to Investigational Drugs as an Academic Oncologist. JAMA Netw Open. 2023;6(2):e230060. doi:10.1001/ jamanetworkopen.2023.0060 26. Mihalko WM. How Do I Get What I Need? Navigating the FDA’s Custom, Compassionate Use, and HDE Pathways for Medical Devices and Implants. J Arthroplasty. 2015;30(6):919922. doi:10.1016/j.arth.2015.01.025 27. Hordijk M, Vermeulen SF, Bunnik EM. The ‘false hope’ argument in discussions on expanded access to investigational drugs: a critical assessment. Med Health Care Philos. 2022;25(4):693-701. doi:10.1007/s11019-02210106-y 28. Blankart K,Naci H,Chandra A.Availability of New Medicines in the US and Germany From 2004 to 2018. JAMA Netw Open. 2022;5(8):e2229231. doi:10.1001/jamanetworkopen.2022.29231 29. Bunnik EM, Aarts N. What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Med Ethics. 2019;20(1):80-80. doi:10.1186/s12910-0190420-8 30. Gould P, Salam T, Kimberly L, Bateman-House A, Fernandez Lynch H. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs. JAMA Netw Open. 2022;5(11):e2239766-e2239766. doi:10.1001/ jamanetworkopen.2022.39766 31. Borysowski J, Ehni HJ, Górski A. Ethics review in compassionate use. BMC Med. 2017;15(1):136136. doi:10.1186/s12916-017-0910-9 32. Bunnik EM, Aarts N. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians’ Views and Experiences in The Netherlands. J Bioethical Inq. 2021;18(2):319-334. doi:10.1007/s11673-02110090-7 33. Finkelstein PE. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes. AMA J Ethics. 2015;17(12):1142-1146. doi:10.1001/journalofethics.2015.17.12.stas11512 34. Weinlander E, Kilbride MK, Joffe S. PatientPhysician Relationship in the Age of Expanded Access to Information-Reply. JAMA. 2019;321(16):1633-1634. doi:10.1001/ jama.2019.1073 35. Chapman CR, Moch KI, McFadyen A, et al. What compassionate use means for gene therapies. Nat Biotechnol. 2019;37(4):352-355. doi:10.1038/s41587-019-0081-7 36. Rozenberg O, Greenbaum D. Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs. Am J Bioeth AJOB. 2020;20(7):89-92. doi:10.1080/15 265161.2020.1779857 37. Reagan-Udall Foundation. Leveraging RealWorld Treatment Experience from Expanded Access Protocols. Reagan Udall Foundation; 2018:1-26.
RkJQdWJsaXNoZXIy MTk4NDMw